Background: Treatment of early-stage mycosis fungoides (MF) consists of topical steroids, phototherapy (UVB), photochemotherapy (psoralen plus UVA [PUVA]), topical nitrogen mustard, or total skin electronbeam irradiation. It has been reported that the same effective UVB dose is safer than PUVA regarding carcinogenicity and produces fewer side effects. Narrowband UVB (311 nm) results in less irritation and erythema and is more effective compared with broadband UVB.
arly-stage mycosis fungoides (MF) presents itself in the skin with erythematous, slightly scaling patches and infiltrated plaques, often at first in the bathing-suit area. The preferential presence of MF lesions on this nonsunlight-exposed region of the body has suggested an ameliorative (protective) role for ultraviolet (UV) radiation. Currently, the treatment of early-stage MF consists of topical steroids, phototherapy (UVB), photochemotherapy (psoralen plus UVA [PUVA]), topical nitrogen mustard, or total skin electron-beam irradiation. The beneficial effects of PUVA therapy for MF have been well documented. 1, 2 In patients with psoriasis, it has been reported that the same effective dose of broadband UVB is safer than PUVA regarding carcinogenicity and produces fewer side effects (such as nausea). 3 Narrowband UVB (311 nm) results in less irritation and erythema compared with broadband UVB, and is more effective in clearing psoriasis lesions. [4] [5] [6] [7] The cumulative, minimal, erythema dose of narrowband UVB required to clear psoriasis is usually less than one-third of that required for broadband UVB. Furthermore, narrowband UVB has relatively more suppressive effects than broadband UVB on systemic immune responses as judged by natural killer-cell activity, lymphoproliferation, and cytokine responses. 8 The beneficial therapeutic responses of narrowband UVB have also been described in several inflammatory dermatoses such as prurigo nodularis, photodermatoses, and atopic eczema. 9, 10 Two reports have been published of narrowband UVB in MF claiming a beneficial response. 11, 12 Regarding the above-mentioned advantages of narrowband UVB over conventional broadband UVB and PUVA therapy, we conducted a retrospec-tive study of patients with clinical and histologically proven early-stage MF treated with narrowband UVB and PUVA.
PATIENTS AND METHODS

Patients
We analyzed retrospectively 56 patients with histologically proven early-stage MF treated with narrowband UVB and PUVA between 1982 and 1998. In the first period of the study most patients were assigned to PUVA; in the second period most patients were assigned to narrowband UVB. Selection was not made according to severity of disease. All patients had stage Ia and Ib disease. The stage of the disease was determined on the basis of the type and extent of skin involvement (without the presence of lymph node, visceral, or blood involvement) according to a modification of the classification scheme by Fuks et al, 13 which can easily be translated into the TNM system. [14] [15] [16] Stage Ia is MF confined to the skin with less than 10% patches and plaques covering the skin surface (ie, T1N0M0 in the TNM classification). Stage Ib is MF confined to the skin with equal or more than 10% patches and plaques covering the skin surface (T2N0M0). No obvious difference between the 2 groups were observed. A total of 21 patients (13 men, 8 women; mean age 45 years) were treated with narrowband UVB and 35 patients (20 men, 15 women; mean age 53 years) were treated with PUVA. We studied the response to treatment, the relapse-free interval, and irradiation dose. Biopsy specimen were taken before and after UV photo(chemo)therapy (Fig 1) .
Methods
Patients were exposed to UV radiation from fluorescent tubes of 2 different types in a square light cabinet with reflecting walls. The cabinet, measuring 1.3 ϫ 1.3 m, contained 60 broadband narrowband UVB lamps (Philips TL100W/01, Eindhoven, The Netherlands) and 32 broadband lamps (Philips TL-100W/09). These lamps emit mainly UVA and less than 0.5% UVB, and are of the same type as are used in many cabinets for PUVA therapy. The spectrum of the narrowband UVB lamps used in this study (TL-01, Philips) is dominated by a strong and narrow peak (bandwidth 2.5 nm) around 311 to 312 nm, with a second peak around 305 nm. Compared with currently used fluorescent UVB lamps, (eg, TL-12, Philips and FS sunlamps, Westinghouse, Bloomfield, Ind) the narrowband UVB lamp we used has a much smaller output at the most erythematogenous effective wavelengths of 300 nm or less. The spectral composition of the UV radiation in the light cabinet was selected by switching on the lamps of the desired type.
The spectral distribution (irradiance) measurements were performed with a calibrated spectroradiometer (model 742, Optronic Laboratories, Orlando, Fla). The irradiances were checked routinely with a UVA or UVB detector (Waldmann AG, Schwenningen, Germany). The irradiance for UVA was, on average, 5.8 mW/cm 2 and, for UVB, 4.1 mW/cm 2 . UVB therapy was conducted twice a week for 3 to 66 months (mean, 14 months). PUVA was administered twice a week for 2 to 37 months (mean, 11 months). The UVB doses were pending during the whole study and chosen with the aim to elicit a slight, but well-tolerable erythema after each exposure. 5, 7 The first exposure was 70% of the predetermined minimal erythema dose on the trunk. Successive doses were determined using the following guideline: if the previous exposure had caused no perceptible effect, the next exposure time was increased by 40%; if the previous exposure induced just a slight erythema, the next exposure time was increased by 20%; and in case of a marked erythema, the same exposure time repeated.
The UVA radiation was administered 2 hours after the intake of 8-methoxypsoralen (8-MOP, Melodinine, Galderma Belgilux, Paurs, Belgium). The doses of UVA were also chosen according to the guideline to cause a slight erythema after each exposure. 5 The first exposure was 70% of the predetermined minimal phototoxic dose. Successive exposures were on the basis of skin reactions: if the previous exposure had not caused a noticeable effect, the next exposure time was increased by 40%; if the previous exposure induced a doubtful erythema, it was increased by 20%; and if it caused a slight erythema, the same exposure time was repeated. This practice was slightly different from that of UVB because 1 minimal phototoxic-dose exposure takes 3 days to develop, whereas 1 minimal erythema dose-UVB exposure develops within 1 day.
Clinical response was rated as follows: complete remission (no disease activity present); partial response (decrease of disease activity Ͼ 50%); and progressive disease (increase of disease activity Ͼ 25%). 17 Before and after therapy, 4-mm punch biopsy specimens were taken from each patient at the site of a representative skin lesion for histologic examination. The specimens were processed routinely and stained with hematoxylin and eosin for light microscopic examination to study the histologic response.
RESULTS
The mean time interval from date of diagnosis to UVB therapy was 3 months, and, for PUVA therapy, was 7 months. The total UVB irradiation dose ranged from 21 (Table I) . Patients who relapsed after treatment with narrowband UVB or PUVA were treated with topical steroids, topical nitrogen mustard, (narrowband) UVB, or PUVA. Acute adverse effects from narrowband UVB reported were burning and pruritus in 1 patient. Two patients reported postinflammatory hyperpigmentation. Patients treated with PUVA reported nausea 3 times and headache twice after systemic psoralen intake; 2 patients reported burning and pain after treatment. All patients continued treatment. The follow-up period was too short to report chronic adverse effects like photoaging and photocarcinogenesis.
DISCUSSION
The results of phototherapy with broadband UVB (280-350 nm wavelength) in the treatment of MF have been reported previously. 18, 19 Ramsay et al 18 reported results from a retrospective study of 32 patients with histologically proven MF and 5 patients with parapsoriasis who were treated with broadband UVB. Of these patients, 84% had patch-stage disease, and 13% had plaque-stage disease. Of these patients 71% achieved a complete remission. The median time to remission was 5 months. None of the patients with plaque-stage disease were responsive to UVB treatment. Of the patients with patch-stage disease, 20% relapsed while on or off therapy. 18 Our results are in accordance with this study, although we did find a response to UVB therapy in patients with MF plaques (Table II) .
Resnik and Vonderheid 19 reported similar results in their 15-year follow-up study of 31 patients with histologically proven cutaneous T-cell lymphoma who were treated with home UVB. In this study, 31 patients underwent home UVB phototherapy (280-350 nm). Of these patients, 21 were classified as having stage Ia disease, 9 had stage Ib disease, and 1 had stage IIa disease according to the TNM system adopted by the MF Cooperative Group. 19 An objective clinical response was observed in 85% of the patients, with 74% achieving a complete clinical and histologic response to therapy. The maximum duration of the remission ranged from 5 months to more than 15 years (median, 51 months). The patients with plaque-stage disease tended to respond less favorably. After maintenance phototherapy was discontinued, 7 patients (23%) had a sustained diseasefree interval lasting more than 58 months (median, Ͼ90 months). Currently, a study by Hofer et al 11 and a study by Clark et al 12 have reported treating early-stage MF with narrowband UVB. However, in the study by Hofer et al 11 only 6 patients with early-stage (noninfiltrated patch) MF and 14 patients with smallplaque parapsoriasis were treated. Because there is ongoing controversy and inconsistent use of the terms "large-" and "small-plaque parapsoriasis," it is perhaps better to abandon these terms and not to include these patients in a study.
In the study by Clark et al, 12 8 patients with histologically proven patch-stage MF were treated with narrowband UVB 3 times weekly using a standard protocol. Complete clearance of MF was achieved in 6 patients in a mean of 9 weeks or 26 treatments (range, 20-37 weeks) and 4 patients obtained prolonged remissions. Mean time to remission was 20 months (range, 11-40 months). Partial response to narrowband UVB or poor histologic improvement was associated with rapid relapse (Table II). 12 The mechanisms of action of (narrowband) UVB therapy in MF are still unknown. In vitro experiments show that UVB decreases the allo-activating and antigen-presenting capacity of Langerhans cells and increases interleukin 2 and interleukin 6 production by human keratinocytes. 20, 21 Increased tumor necrosis factor has also been detected after UVB irradiation. Possibly, UV light suppresses the function of the neoplastic population of clonal T cells in the skin and serves as an immune up-regulator. 20 Also the overall effect of PUVA in MF may be a result of preferential mitotic inhibition, killing of neoplastic T cells, or both in the skin and superficial capillaries. Other PUVA effects in MF include psoralen adduct damage to cell organelles (eg, mitochondria) and alterations in the immune system. 22, 23 McGregor et al 24 indicated p53 mutations in tumor-stage MF; a mutation spectrum strikingly similar to that reported in nonmelanoma skin cancer and characteristic of DNA damage caused by UVB radiation. 24 Therefore, caution using UV therapy in patients with MF was advised.
In our retrospective study, we found that narrowband UVB therapy for patients with early-stage MF is an effective treatment. Among our patients, 81% achieved complete remission, 19% achieved partial remission, and none showed progressive disease. Mean relapse-free interval was 24.5 months. Considering the benefits of UVB therapy over PUVA, it may be advisable when treating early-stage MF to start with narrowband UVB therapy and, if there is progression during therapy or no response to therapy, switch to PUVA therapy.
